HC Wainwright Has Optimistic Opinion of RVMD FY2026 Earnings

Revolution Medicines, Inc. (NASDAQ:RVMD) – Investment analysts at HC Wainwright boosted their FY2026 EPS estimates for Revolution Medicines in a report issued on Friday, November 6th. HC Wainwright analyst R. Burns now anticipates that the company will earn ($7.42) per share for the year, up from their previous estimate of ($9.20). HC Wainwright currently has a “Buy” rating and a $350.00 target price on the stock. The consensus estimate for Revolution Medicines’ current full-year earnings is ($7.88) per share. HC Wainwright also issued estimates for Revolution Medicines’ Q4 2026 earnings at ($1.02) EPS, Q1 2027 earnings at ($0.56) EPS, Q2 2027 earnings at ($0.14) EPS, Q3 2027 earnings at $0.37 EPS, Q4 2027 earnings at $0.52 EPS and FY2027 earnings at $0.20 EPS.

Revolution Medicines (NASDAQ:RVMD) last issued its quarterly earnings data on Wednesday, November 4th. The company reported ($1.90) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.35) by $0.45. The business had revenue of $197.56 million during the quarter, compared to analysts’ expectations of $25.58 million. During the same quarter last year, the business posted ($1.61) EPS.

Several other research analysts have also commented on RVMD. UBS Group boosted their price objective on Revolution Medicines from $220.00 to $265.00 and gave the stock a “buy” rating in a report on Friday, August 28th. Wall Street Zen upgraded shares of Revolution Medicines from a “sell” rating to a “hold” rating in a research report on Saturday. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $248.00 target price on shares of Revolution Medicines in a research note on Thursday, August 27th. Truist Financial reiterated a “buy” rating and set a $261.00 target price (up from $241.00) on shares of Revolution Medicines in a research report on Thursday, November 5th. Finally, Bank of America cut their price target on shares of Revolution Medicines from $265.00 to $264.00 and set a “buy” rating for the company in a research note on Friday, October 9th. One analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Revolution Medicines currently has a consensus rating of “Moderate Buy” and a consensus price target of $263.15.

Revolution Medicines Stock Performance

NASDAQ:RVMD opened at $200.15 on Tuesday. The business’s 50-day moving average price is $196.73 and its two-hundred day moving average price is $157.98. Revolution Medicines has a twelve month low of $61.50 and a twelve month high of $224.31. The stock has a market cap of $42.90 billion, a P/E ratio of -21.97 and a beta of 1.44. The company has a quick ratio of 11.38, a current ratio of 11.38 and a debt-to-equity ratio of 0.40.

Institutional Trading of Revolution Medicines

A number of hedge funds have recently bought and sold shares of the company. IFG Advisory LLC lifted its holdings in shares of Revolution Medicines by 117.0% in the 3rd quarter. IFG Advisory LLC now owns 217 shares of the company’s stock worth $45,000 after acquiring an additional 117 shares during the last quarter. Optas LLC purchased a new stake in shares of Revolution Medicines in the 3rd quarter valued at $203,000. Danica Pension Livsforsikringsaktieselskab purchased a new stake in shares of Revolution Medicines in the 3rd quarter valued at $242,000. Danske Bank A S grew its holdings in shares of Revolution Medicines by 7.6% during the 3rd quarter. Danske Bank A S now owns 85,200 shares of the company’s stock valued at $17,488,000 after purchasing an additional 6,000 shares during the last quarter. Finally, Aberdeen Group plc grew its holdings in shares of Revolution Medicines by 303.1% during the 3rd quarter. Aberdeen Group plc now owns 576,371 shares of the company’s stock valued at $118,306,000 after purchasing an additional 433,393 shares during the last quarter. Institutional investors own 94.34% of the company’s stock.

Insider Buying and Selling at Revolution Medicines

In other Revolution Medicines news, CFO Jack Anders sold 4,053 shares of Revolution Medicines stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $199.24, for a total transaction of $807,519.72. Following the completion of the sale, the chief financial officer owned 119,216 shares of the company’s stock, valued at $23,752,595.84. The trade was a 3.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Alan Sandler sold 6,309 shares of Revolution Medicines stock in a transaction dated Tuesday, September 29th. The stock was sold at an average price of $202.14, for a total value of $1,275,301.26. Following the sale, the insider directly owned 52,559 shares of the company’s stock, valued at approximately $10,624,276.26. This trade represents a 10.72% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 290,991 shares of company stock valued at $59,422,765. 7.60% of the stock is currently owned by company insiders.

About Revolution Medicines

Revolution Medicines, Inc is a biotechnology company focused on developing targeted therapies for patients with RAS-driven cancers. Founded in 2014 and headquartered in Redwood City, California, the company’s research centers on RAS proteins, which can contribute to the growth of many cancers.

The company’s pipeline includes drug candidates designed to inhibit mutant RAS proteins, including daraxonrasib (RMC-6236), which targets multiple RAS variants, and candidates directed at specific KRAS mutations.